Adverse Reactions to Anti-Infective Vaccines: an Emerging Problem in the COVID-19 Era

Carmelo Escudero, MD, PhD1,*
Patricia Prieto-Montaño, MD2
M Teresa Audicana, MD, PhD3

Abstract

Purpose of review Vaccines are an essential tool for preventing infectious diseases and reducing associated morbidity and mortality. Vaccination has a significant impact at both individual and community levels, and COVID-19 vaccination programs are a new example of the great value of this public health strategy. However, adverse reactions, especially severe reactions such as anaphylaxis, prevent these programs from progressing properly, thus limiting vaccination uptake in the population.

Recent findings The frequency of reactions and types of vaccine components, with special attention to COVID-19 vaccines studies, provides information on the magnitude and causes of adverse events. The understanding of mechanisms involved has made it possible to adequately guide diagnosis, especially to COVID-19 vaccine components, such as polyethylene glycol, trometamol, and polysorbate-80.

Summary This review focuses on adverse reactions to vaccines, with emphasis on allergic reactions. A diagnostic pathway is suggested that, on the one hand, enables to take the necessary precautions in persons with a history of allergy to vaccine components or allergic reactions to vaccines and, on the other, supports administration of subsequent doses. The overall objective is to ensure that people with allergy can be vaccinated in the same way as the rest of the population, and that they are offered alternatives where necessary.
Introduction

Vaccines are one of the most cost-effective tools in healthcare interventions. They prevent infectious diseases, reduce morbidity, and save innumerable lives. However, vaccines can cause adverse reactions, which may range from local and mild to systemic and severe. While severe adverse reactions can occur after the administration of the vaccine, for most people, the benefits of vaccination overcome the potential risk of experiencing such a reaction. Nevertheless, the fear of an adverse reaction may lead to reticence towards vaccination, thus leaving the individual in danger of not being protected against the disease and limiting collective immunity. Millions of vaccine doses are administered throughout the world every year, although the rate of reactions reported is low, especially anaphylaxis with only 1.3 cases per million vaccinations [1].

The development of new vaccines against severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) constitutes an unprecedented achievement in modern science, since these were the first vaccines created with messenger RNA (mRNA)-based technology. Once the first temporary authorizations were given by the regulatory agencies for BNT162b2, mRNA-1273, and AZD1222, from December 2020 to May 2022 it has been estimated that 11.9 billion doses have
been administered worldwide, and that 65.9% of the world's population has received at least one dose of COVID-19 vaccine [2]. Anaphylaxis after SARS-CoV-2 vaccination is rare, affecting 5 persons per million who receive the vaccination [3].

We review the type and frequency of adverse reactions associated with the administration of anti-infective vaccines, both traditional products and COVID-19 vaccines. Our study also provides guidelines for accurate diagnosis of these reactions and indications for controlled administration of new doses of the vaccine. Our objectives were to improve individual safety and ensure that as many people as possible can be vaccinated.

Immediate and non-immediate reactions

The WHO recommends classifying drug reactions based on the onset of symptoms. The two general types are immediate (< 1 h) and delayed reactions (> 1 h). Immediate reactions are generally IgE-mediated and carry a risk of systemic allergic reaction (anaphylaxis). Delayed reactions can be caused by various mechanisms, but are rarely IgE-mediated. Allergic reactions to vaccines are immune-mediated and account for a small percentage of AEFI [4].

Immediate reactions

Systemic allergic reactions are severe AEFI. Although uncommon, anaphylaxis is a severe and potentially life-threatening reaction [5]. It is highly probable when its signs appear rapidly (generally < 30 min after injection) [6], affecting various organs and systems (urticaria, erythema, bronchospasm, nausea, vomiting, diarrhea, hypotension with tachycardia, and/or loss of consciousness) [5]. It should be differentiated from other clinical presentations, such as vasovagal reactions (fainting) [7], and symptoms related to anxiety [8]. In these cases, symptoms appear during the injection or immediately after. They are characterized by pallor, cold, and clammy skin, sweating, hyperventilation or normal breathing, hypotension with bradycardia, and, occasionally, self-limiting loss of consciousness, with a favorable response to decubitus positioning. It is essential to differentiate between vasovagal reactions and anaphylaxis.

Non-immediate reactions

Fever, asthenia, myalgia, and/or headache are common non-immediate reactions, as are pain, reddening, and/or mild swelling at the injection site. These should not be a contraindication to future doses [9]. Extensive local reactions and chronic subcutaneous nodules appear 24–72 h after administration and are usually type-IV hypersensitivity reactions. Their frequency can be reduced by deep injection into the thigh [10]. Serum-like sickness (type-III), which progress with skin rash, fever, malaise, and polyarthralgia or polyarthritis, occur up to 1–2 weeks after vaccination if the patient has received the vaccine.
more than once. In very rare cases, they have been associated with inactivated vaccines against influenza and HBV [11, 12].

Reactions to vaccine components

Reactions to vaccines may be due to the microbial antigen, residual proteins from production process, antimicrobial agents, stabilizers, preservatives, or any other element used during the packaging and administration processes [13]. Vaccine antigen is an infrequent cause of allergy. However, associated anaphylaxis has been reported, for example, with influenza vaccine and a nontoxic mutation of diphtheria toxin (CRM197) in the pneumococcal conjugate vaccine [14, 15]. Table 1 shows the main components, their function, vaccines that contain them, and reaction type [16].

Aluminum salts

Adjuvants used in vaccines to boost the immunogenic response, it do not cause anaphylaxis, although they trigger local reactions such as subcutaneous nodules or type-IV reactions. The latter occur 24–72 h after administration, and their risk increases with the number of doses received. Local reactions do not contraindicate administration of vaccines that contain aluminum [17]. Research is under way on the allergenicity of new adjuvants such as squalene derivatives (MF59, AS03, AF03) [18•].

Gelatin

Vaccine stabilizer is essentially porcine in origin and frequently cross-reacts with bovine gelatin. Patients who are sensitized to beef/pork also become sensitized to their gelatins, thus increasing the risk of experiencing reactions with vaccines that contain them [19]. Specific IgE (sIgE) has been detected in anaphylaxis induced by gelatin in the MMR [20]. Gelatin can also be a source of galactose-alfa-1,3-galactose (alfa-gal) [21]. Anaphylaxis has been reported after vaccination against MMR, varicella zoster virus, and DTaP/IPV in patients with a history of allergy to red meat [22•]. Hydrolysis/elimination of gelatin has reduced the frequency of systemic reactions [23]. Administration of gelatin-containing vaccines is contraindicated in patients who have previously experienced anaphylaxis to this component.

Thiomersal

Preservative synthetized from ethylmercuric chloride and thiosalicylic acid induces mild late local reactions (contact dermatitis). Positive patch test result
| Component | Function                  | Reaction                                                | Vaccine                                      |
|-----------|---------------------------|---------------------------------------------------------|----------------------------------------------|
| Aluminum hydroxide and aluminum phosphate | Adjuvant                   | Local:                                                   | Adenovirus                                  |
|           |                           | - Granulomas                                            | Anthrax                                      |
|           |                           | - Contact dermatitis                                    | DTAp/Tdap                                    |
|           |                           |                                                         | Haemophilus (Hib)                            |
|           |                           |                                                         | Hepatitis A/B                                |
|           |                           |                                                         | HPV                                          |
|           |                           |                                                         | Japanese Encephalitis                        |
|           |                           |                                                         | Meningococcal                                |
|           |                           |                                                         | Pneumococcal                                 |
| Gelatin   | Stabilizer                | Local urticaria                                         | Influenza                                    |
|           |                           |                                                         | MMR                                          |
|           |                           |                                                         | Rabies                                       |
|           |                           |                                                         | Typhoid                                      |
|           |                           |                                                         | YF                                           |
|           |                           |                                                         | Zoster                                       |
| Alpha-gal | Stabilizer                | Anaphylaxis                                             | DTAp/IPV                                     |
|           |                           |                                                         | MMR                                          |
|           |                           |                                                         | Varicella                                    |
| Thiomersal| Preservative              | Contact dermatitis                                      | Influenza                                    |
|           |                           |                                                         | Td                                           |
| Beta-propiolactone | Inactivation of virus       | Delayed local reaction                                  | COVID-19 (Sinovac, Sinopharm)               |
|           |                           |                                                         | Rabies human diploid cell vaccine (HDVC)     |
| Formaldehyde | Inactivation of virus     | Local:                                                   | DTAp/Tdap                                    |
|           |                           | - Contact dermatitis                                    | Hepatitis B                                  |
|           |                           | - Systemic contact dermatitis                           | Hib                                          |
|           |                           |                                                         | Influenza                                    |
|           |                           |                                                         | Japanese Encephalitis                        |
|           |                           |                                                         | Meningococcal                                |
|           |                           |                                                         | Polio                                         |
|           |                           |                                                         | Typhoid                                      |
| Neomycin  | Antibiotic                | Anaphylaxis                                             | DTAp                                          |
|           |                           |                                                         | Hepatitis A                                  |
|           |                           |                                                         | Influenza                                    |
|           |                           |                                                         | MMR                                          |
|           |                           |                                                         | Polio                                         |
|           |                           |                                                         | Rabies                                        |
|           |                           |                                                         | Smallpox                                     |
|           |                           |                                                         | Varicella                                    |
|           |                           |                                                         | Zoster                                       |
Table 1 (continued)

| Component          | Function                                      | Reaction                        | Vaccine                       |
|--------------------|-----------------------------------------------|---------------------------------|-------------------------------|
| Natural latex      | Present in vial stopper or syringe plunger within the conditioning material | Delayed local reaction         | Anthrax                       |
|                    |                                               | Urticaria                       | DTaP/Tdap/Td                  |
|                    |                                               | Anaphylaxis                     | Hepatitis A/B                 |
|                    |                                               |                                 | Influenza                     |
|                    |                                               |                                 | Meningococcal                 |
|                    |                                               |                                 | Rotavirus                     |
|                    |                                               |                                 | YF                            |
| Egg proteins       | Residual medium                               | Anaphylaxis                     | Influenza                     |
|                    | Stabilizer                                    |                                 | MMR                           |
|                    |                                               |                                 | Rabies                        |
|                    |                                               |                                 | YF                            |
| Yeast              | Residual medium                               | Anaphylaxis                     | DTaP                          |
|                    | Medium nutrient                               |                                 | Hepatitis A/B                 |
|                    |                                               |                                 | Meningococcal                 |
|                    |                                               |                                 | Pneumococcal                  |
|                    |                                               |                                 | Typhoid                       |
|                    |                                               |                                 | HPV                           |
| Milk proteins      | Residual medium                               | Anaphylaxis                     | DTaP/Tdap                     |
|                    | Medium nutrient                               |                                 | Hib                           |
|                    |                                               |                                 | Influenza                     |
|                    |                                               |                                 | Meningococcal                 |
| Polyethylene glyco| Surfactant of mRNA                             | Anaphylaxis                     | COVID-19                      |
| Trometamol         | Stabilizer                                    |                                 | DTaP-IPV-HB-Hib               |
|                    |                                               |                                 | Hib-N. Meningitidis           |
|                    |                                               |                                 | Meningococcal                 |
| Polysorbate-80     | Surfactant                                    | Non-immunological anaphylaxis   | COVID-19                      |
|                    |                                               | Local                           | DTaP                          |
|                    |                                               |                                 | Hepatitis A/B                 |
|                    |                                               |                                 | Influenza                     |
|                    |                                               |                                 | Meningococcal                 |
|                    |                                               |                                 | Pneumococcal                  |
|                    |                                               |                                 | Rotavirus                     |
|                    |                                               |                                 | HPV                           |
|                    |                                               |                                 | Zoster                        |

Modified from Sampath V et al. [16]

with thiomersal does not contraindicate administration of a vaccine [24]. This preservative has been used less frequently in recent years to prevent toxicity in children.
**Beta-propiolactone and formaldehyde**

Both beta-propiolactone and formaldehyde are used to inactivate viruses and toxins. Six percent of people who receive booster doses of the human diploid cell rabies vaccine develop a response induced by immune-complexes at 2–21 days. This response was associated with altered beta-propiolactone in human albumin in the vaccine [25, 26]. The Sinopharm/Sinovac vaccines have recently been using beta-propiolactone to inactivate SARS-CoV-2 [27, 28••]. Formaldehyde is found in small amounts in vaccines. Systemic contact dermatitis caused by formaldehyde in the influenza vaccine has been reported [29].

**Antibiotics**

Neomycin, kanamycin, streptomycin, and/or polymyxin B are added as preservatives to prevent contamination and may be present in trace amounts. Allergic reactions are very rare, and an IgE-mediated mechanism has been demonstrated in only a few cases. Some neomycin-allergic patients may experience mild local reactions 48–96 h after injection, but does not contraindicate future vaccination [30]. Vaccines containing antibiotics are contraindicated in patients with history of anaphylaxis after administration of the specific antibiotic [31].

**Latex**

Component of the cap of the vial of some vaccines or the seal of the plunger in syringes. Reactions to latex after vaccination are very rare. The VAERS reported that 0.01% of persons with a history of latex allergy who received a latex-containing vaccine experienced allergic reactions [32]. Vaccines in preloaded vials or syringes containing latex are contraindicated in patients with history of latex-induced anaphylaxis [33].

**Proteins**

Reactions to residual proteins include those caused by yeast and milk and egg proteins, with the latter being the most frequent.

The egg protein content depends on the manufacturing process and is very low if the vaccine is prepared using chicken embryo fibroblasts (measles, mumps, rabies, and MMR) (0.2–42 μg/mL) and somewhat higher if embryonated chicken eggs are used (influenza [0.02–1.0 μg/dose], and YF). Final product contains trace amounts of protein, 100,000 times lower than the threshold that would cause a reaction in a challenge test. Highest concentration of proteins is found in the YF [34]. Children with egg allergy tolerate
not only the MMR and influenza vaccines [35, 36], but also the YF, even in those with history of anaphylaxis to egg [37, 38•]. The CDCs and the Advisory Committee on Immunization Practices recommend a 30-min observation period in children with moderate egg allergy after influenza vaccination; in those with severe allergy, the vaccine should be administered at a center where severe reactions can be managed [39, 40].

Allergic reactions to the DTaP, Tdap, oral polio, and MMR in children with milk allergy are rare. These vaccines may contain nanograms of residual casein, and most allergic patients tolerate them [41]. EAACI position paper recommends standard vaccination in children with milk allergy [13].

Yeasts are found in the HBV and HPV, manufactured using cell cultures of *Saccharomyces cerevisiae*. Residual protein content is minimum, and allergic reactions are extremely rare. However, if yeast allergy is suspected, sIgE should be determined and skin tests performed before their administration [42]. Yeast is also used in the production of the carrier protein CRM197; therefore, its proteins may be found in vaccines such as pneumococcal conjugate vaccine 13, meningococcal, and oral typhoid vaccines [43].

### COVID-19 vaccine components

The potential allergenic excipients in currently available COVID-19 vaccines are polyethylene glycol (PEG), trometamol, and P80.

### Polyethylene glycol (macrogol)

While unusual, allergy to PEG has been increasingly reported in recent years [44]. Patients diagnosed with allergy to this excipient generally experience recurrent systemic reactions with several types of drugs. This observation, together with the fact that the presence of the excipient may vary between formulations (oral, parenteral, and commercial brand) has led to consider PEG as a hidden allergen in drugs.

Moreover, allergy workup for PEG is complex, since skin testing carries a risk of anaphylaxis, to the extent that they are considered as risky as exposure to a drug [45]. Intradermal test should be systematically avoided or performed with caution, especially in patients with comorbid conditions or history of severe reaction.

Cross-reactivity exists between PEG of different molecular weights, whereas others state that only high-molecular-weight PEG (> 3500 Da) and that contained in parenteral drugs induce allergic responses.

### Trometamol

Excipient in various contrast agents, including gadolinium and iodated agents, it is widely used in buffer solutions in topical products, cosmetic industry, and medications (fosfomycin, ketorolac, and some vaccines). One case of anaphylaxis induced by gadolinium has been reported [46].
Polysorbate-80

Also known as propylene glycol, Tween 80, and E433, polysorbate-80 (P80) is increasingly found in foods and drugs, ranging from biologic to oncologic products. There is some controversy over its cross-reactivity with PEG [44].

Drugs to which it has been thought to induce allergic reactions include vitamins, parenteral corticosteroids, etoposide, erythropoietin, darbepoetin, acyclovir, factor VIII, and monoclonal antibodies used in autoimmune diseases and cancer.

Prevalence of allergy to polysorbate-80 is very low, although it is expected to increase, since more than 70% of biologic drugs contain polysorbate 20 or 80. Some studies show that it only induces allergy when administered parenterally [47].

Adverse reactions to specific vaccines

Diphtheria, tetanus, and pertussis

Reaction may be due to a vaccine antigen or a preservative (thiomersal), adjuvants (aluminum salts), stabilizers (gelatin in the pertussis component), culture medium (casein), and other causes (latex).

Systemic reactions are uncommon and usually mild (fever, joint pain, and general malaise). There have been reports of cases of urticarial/angioedema with positive allergy workup for diphtheria and tetanus toxoid and of systemic allergic reactions (0.2%), some of which were associated with gelatin [19]. Anaphylaxis has also been reported after booster dose of diphtheria-tetanus, with positive results for both toxoids [48].

Successful desensitization has been reported in patients with allergy to vaccine toxoids [49]. Nevertheless, children who react to the diphtheria-tetanus vaccines may lose hypersensitivity over time. Therefore, future use of this vaccine should be evaluated [50].

Measles-mumps-rubella

Reactions may be caused by virus contained in the vaccine or components used during manufacture (gelatin, egg, dextran, neomycin, latex). Reactions to virus are mainly mild and transient.

Most allergic reactions are caused by gelatin. sIgE to gelatin has been reported in 92% of children who experienced a systemic reaction to the measles vaccine, and in up to 27% of those who experienced a reaction to the MMR [51]. Some patients who reacted to the MMR became sensitized owing to the gelatin in the DTaP vaccine [52].

Dextran, present in some MMR, can lead to severe immediate reactions; therefore, vaccines containing dextran have been withdrawn.
Influenza

Trivalent/quadrivalent inactivated influenza vaccines are generally harmless, although injection site reactions are common (>1%). Fever, general malaise, and myalgia are also relatively frequent, especially in small children who have not been previously exposed to vaccine antigens [19].

Adverse reactions occur mainly to thiomersal, gelatin, and latex. Gelatin is found at concentrations of 250 μg/0.5 to 2000 μg/0.2 mL, although this is an uncommon cause of anaphylaxis.

Some studies have shown that the trivalent/quadrivalent inactivated vaccines, which have a low ovalbumin content, can be safely administered in patients with egg allergy [53, 54].

Yellow fever

Anaphylaxis to YF may be due to egg proteins and gelatin. While American reports show good tolerance to single dose in children with severe egg allergy, EAACI recommends an allergy study before administration [13].

Haemophilus influenzae type B

Reports of anaphylaxis after vaccination against Hib were not confirmed by allergy workup. In anaphylaxis after conjugate Hib vaccine administration, causative agent was the nontoxic conjugate protein of diphtheria toxin, CRM197. This finding highlights the value of allergy study, since it may be contained in other vaccines [55].

Hepatitis B virus

HBV may contain small amounts of yeast proteins (around 25 mg/dose) [16]. Allergic reactions are extremely rare. A review of more than 180,000 allergic reactions registered in the VAERS revealed that 15 could be attributed to yeast proteins, although sensitization was not confirmed [42]. An anaphylaxis has been reported after administration of the HBV, with the causative allergen being latex in the cap [56].
Poliomyelitis

It contains alfa-lactalbumin, rarely responsible for reactions in milk-allergic children [57]. Both injected and oral poliomyelitis vaccines contain traces of neomycin, streptomycin, and polymyxin b.

Varicella

It contains gelatin, responsible for anaphylaxis [52].

Human papillomavirus

In most cases, anaphylaxis appears after the first dose and are less frequent after the second one. Allergy is biologically possible owing to the viral particles (highly immunogenic when injected), residual yeast, and polysorbate-80, included in the quadrivalent vaccine as a stabilizer. However, no positive results have been recorded for any of the three components in cases of anaphylaxis. HPV is associated with syncope in adolescents [58].

Pneumococcus

There has been one report of anaphylaxis with pneumococcal conjugate vaccine 13, attributed to the nontoxic conjugate protein of diphtheria, CRM197 [15].

COVID-19 vaccines

Most frequently reported events are general disorders (fever and pain at the injection site), nervous system complaints (headache and dizziness), and musculoskeletal disorders (myalgia and arthralgia). However, other more severe effects have been reported, including anaphylaxis (Table 2) [59••].

A meta-analysis of adverse reactions to COVID-19 vaccines (Pfizer/Moderna) in adults confirmed a female predominance, for both anaphylactic and nonanaphylactic reactions [60••]. Reactions induced by a lipid derivative bound to PEG are more frequent in women. They are thought to be due to use of cosmetics or effect of hormones [61].

Local skin reactions are frequently reported with mRNA vaccines and include late local reaction (“COVID arm”), urticaria/angioedema, and self-limiting morbilliform rash. Other reported skin reactions include erythema multiforme, pernio (chilblains), herpes simplex reactivation reactions, and pityriasis rosea-like reactions, which mainly affect high-risk patients [62••, 63].
| Reaction                  | Associated vaccines                          | Incidence (× 100,000) | Origin                                      | Mechanism involved                                                                 | Clinical symptoms                                                                 |
|--------------------------|---------------------------------------------|-----------------------|---------------------------------------------|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Anaphylaxis              | Pfizer                                      | 1.1                   | PEG and Trometamol                          | Type I hypersensitivity                                                            | Urticaria/angiodyema Airway and/or breathing and/or cardiovascular compromise   |
|                          | Moderna                                     |                       | Polysorbate-80                              | IgE mediated                                                                        |                                                                                  |
|                          | Vector adenoviral                            |                       | Activation of MRGPRX2 receptor              |                                                                                  |                                                                                  |
|                          | AstraZeneca                                 |                       |                                             |                                                                                  |                                                                                  |
|                          | Janssen                                     |                       |                                             |                                                                                  |                                                                                  |
|                          | Adenoviral vector vaccines:                 | 0.73                  | Immune response to viral stimulus           | Activation of the platelets by the anti-PF4 antibodies that cause arterial/venous    | Cerebral/abdominal thrombosis, low platelet count, D-dimer (>4 times normal values) |
|                          | AstraZeneca                                 |                       |                                              | thrombosis and platelet consumption                                                | Abs anti PF4                                                                      |
|                          | Janssen                                     |                       |                                              |                                                                                    |                                                                                  |
| Myocarditis Pericarditis | Pfizer                                      | 1.2                   | Spike protein generated                     | Cross-reaction of myocardial proteins with spike protein                            | Retrosternal chest pain, respiratory distress                                    |
|                          | Moderna                                     |                       |                                              | Non-immunological inflammatory response                                             | Troponin elevation                                                               |
|                          |                                              |                       |                                              |                                                                                    | C-reactive protein elevation                                                      |
|                          |                                              |                       |                                              |                                                                                    | EKG changes                                                                      |
| Guillain Barré syndrome  | Adenoviral vector vaccines:                 | AstraZeneca 5.14      | Immune response to viral stimulus           | Acute peripheral nerve neurological disease                                        | Ascending weakness in legs and cranial nerves                                   |
|                          | AstraZeneca                                 | Janssen 0.78          |                                              | Abs antigangliosides                                                               | Flaccid paralysis                                                                |
|                          | Janssen                                     |                       |                                              | Complement activation                                                              | Distal paraesthesia or quadriplegia with facial diplegia                         |
|                          |                                              |                       |                                              |                                                                                    | Cerebrospinal proteins increased with normal cellularity                         |
| Acute transverse myelitis| Adenoviral vector vaccine:                  | Sporadic or unknown   | Immune response to viral stimulus           | Immune-mediated neurological disease                                                | Quadriplegia or paraplegia                                                      |
|                          | AstraZeneca                                 |                       |                                              |                                                                                    |                                                                                  |
| Acute disseminated       | All                                          | Sporadic or unknown   | Immune response to viral stimulus or spike  | Molecular mimicry that generates autoimmune response                               | Acute disseminated encephalomyelitis                                            |
| encephalomyelitis        |                                              |                       | protein generated                           |                                                                                    |                                                                                  |
| Bell's palsy              | Pfizer                                      | Sporadic or unknown   | Immune response to viral stimulus or spike  | Molecular mimicry that generates autoimmune response                               | Unilateral facial paresis or paralysis                                          |
|                          | Moderna                                     |                       | protein generated                           |                                                                                    |                                                                                  |
| Reaction          | Associated vaccines | Incidence ($\times 100,000$) | Origin          | Mechanism involved                     | Clinical symptoms                                      |
|------------------|---------------------|--------------------------------|-----------------|----------------------------------------|--------------------------------------------------------|
| Rhabdomyolysis   | All                 | Sporadic or unknown            | PEG, Trometamol, Polysorbate-80 | Exaggerated response to adjuvants       | Myalgia, dark urine, high plasma creatine kinase, and urine myoglobin |
Other reactions include persistent enlarged lymph nodes (both axillary and supraclavicular). This reaction hampered screening for and diagnosis of breast cancer, as it interfered with the mammogram and lymph node assessment [64]. COVID-19 vaccine should also be considered in follow-up of other malignant neoplasms with the potential to cause adenopathy at this level (head and neck cancer, lymphoma, and melanoma).

Severe allergic reactions have been reported, especially with the two mRNA vaccines (Pfizer/Moderna); reactions to viral vectors are less frequent [65–67]. For patients who have experienced anaphylaxis, Medicines Agencies and Scientific Societies recommend an allergy study before additional doses [68•, 69, 70]. Recently reported data indicate a frequency of three moderate-severe reactions per 100,000 vaccines administered. Women and subjects with history of adverse drug reactions seem to be at greater risk of moderate-severe adverse reactions to mRNA vaccines. Within the vaccines used, the most severe and common reactions reported were with Moderna, even though 5 times more Pfizer was administered in the study population (Audicana MT, personal communication, SEAIC, Zaragoza, Spain, October 20, 2021). The results are consistent with others that point to a non-allergic mechanism associated with the mRNA vaccines [71•]. Structures other than PEG may play a role in the allergenicity of these vaccines. This hypothesis would explain why patients previously diagnosed with allergy to PEG-asparaginase tolerated Pfizer vaccine [72]. Several authors suggest pathophysiological mechanisms other than IgE in these adverse reactions.

1. Complement activation-related pseudoallergy. This mechanism is based on the presence of pre-existing PEG IgG/IgM. Once the vaccine has been administered, they activate complement, thus generating anaphylatoxins (C3a, C4a, and C5a), which in turn degranulate mastocytes [73]. In a report on 22 patients, possible IgE-mediated anaphylaxis and complement activation-related pseudoallergy (CARPA) were evaluated after vaccination with mRNA vaccines. Authors concluded that reactions were probably due to the CARPA mechanism owing to anti-PEG IgG [71•]. However, further studies are necessary.

2. Phenomena associated with ACE-2 receptor stimulation. The S1 subunit of the spike protein, detected in the bloodstream up to 2 weeks after vaccination [74], can trigger thrombosis and other adverse inflammatory reactions, including activation of the kallikrein-bradykinin system [75]. This mechanism could explain episodes of urticaria/angioedema induced by COVID-19 and by vaccination, in much the same way as the mechanism involved in episodes caused by angiotensin-converting enzyme inhibitors.

3. Antibody-dependent enhancement and/or cytokine storm. Cytokine storm has three basic characteristics: high cytokine levels, acute systemic inflammatory symptoms, and organ failure. Antibody-dependent enhancement (ADE) has been associated with vaccines (syncytial respiratory virus, and dengue). Increased levels of biomarkers such as D-dimer, ferritin, and C-reactive protein are associated with a poor prognosis for COVID-19, and the spike protein S1 subunit can induce pro-inflammatory responses [76]. This syndrome has been recognized as vaccine-induced immune thrombotic thrombocytopenia, as confirmed first for the AstraZeneca vaccine [77] and later few cases have been reported with other vaccines [59••]. In the case of reactions with the first dose of the Pfizer vaccine, some authors propose a 2-step vaccination protocol with 0.05 mL, followed by 0.25 mL with a 30-min interval between the steps. However, the immune response induced should be tested [78].

4. Finally, the involvement of the activation of MRGPRX2 receptor as inducer of non-IgE-mediated anaphylaxis via pharmacologic agents cannot be excluded [79].
Diagnosis of hypersensitivity reactions to anti-infective vaccines

First, it is essential to grade the allergic reaction after vaccination, especially to determine anaphylaxis [80]. Serum tryptase assay in the 2 h following reaction and basal determination, 48 h after the reaction, can help to guide diagnosis. Significant increase in serum levels after reaction is a marker of mastocyte-mediated response [81].

Approach to suspected anaphylaxis

In patients with a history of allergic reaction to vaccines or vaccine components, every effort should be made to investigate the composition of the vaccine. Manufacturer’s summary of product characteristics should be reviewed to identify causative agent. In reactions occurring after the first dose of the vaccine, possibility that the vaccine antigen is responsible decreases [82]. In this case, it is relevant to analyze a history of allergy and vaccine components other than vaccine antigen.

Need for subsequent doses

Patients who have experienced a severe reaction are considered at risk for a subsequent dose. However, without a diagnosis, allergy is only a presumption, and subsequent doses may be delayed without justification [83]. The need for future doses with the same vaccine or a vaccine containing similar components should be evaluated by the clinician. In serially administered vaccines, it should evaluate whether the severity of the reaction is reason enough for cancelling new doses.

Skin tests with vaccines and vaccine components

When a severe reaction to a vaccine is suspected and patient needs to be vaccinated in the future, it should be performed skin tests with vaccine or its components (Fig. 1) [84]. These tests should only be done by allergists trained. First step should involve prick test using undiluted vaccine (1:1), unless the reaction that led to the workup was anaphylactic shock, in which case the vaccine must be diluted [19]. If the result is negative, intradermal testing (0.02 mL) should be performed with the vaccine diluted 1:100 in 0.9% saline solution. The 1:10 dilution could prove to be irritant and yield false positives, especially with the influenza, MMR, and varicella vaccines. The same is true of the 1:1,000 dilution for the DT, DTaP, and influenza vaccines [85].
In the case of COVID-19 vaccines, it is sufficient to perform skin tests with remains of a vaccine that was constituted in the previous 6 h. These should be prick tests with the undiluted vaccine and intradermal tests with vaccine diluted 1:100. Skin tests with Pfizer vaccine have proven to be nonirritant [86]. Interpretation of intradermal tests with this vaccine may be limited, since patients who have received 1–2 doses may experience delayed reactions with induration [87]. These reactions are not relevant for diagnosis. In case of immediate positive result, skin testing with PEG can be considered. However, its clinical usefulness is limited [82].

Non-immediate local reactions can be assessed using patch tests. However, this approach is not essential when deciding on future vaccinations.

It is not necessary to perform a systematic preventive allergy workup for a vaccine before in persons who have experienced severe allergic reactions to drugs and/or foods [68•], except for patients with confirmed allergy after ingestion of gelatin. In this case, it would be appropriate to perform skin test with the gelatin-containing vaccine [51].
Serum-specific IgE to microbial and vaccine components

sIgE to microbial components is not useful in the diagnosis of allergic reactions to vaccines; in any case, testing is not available for all components [13]. When tests can be performed for some components (e.g., tetanus toxin, ethylene oxide, milk, egg, gelatin, yeast, and latex), its value for predicting an allergic reaction is low, because the patients with a positive result who experience reactions to a vaccine containing these components are scarce [53].

Administration of vaccines

Immediate reactions

Patients should be classified by the reaction severity [70].

Patients with mild reactions (erythema, self-limiting acute urticaria, and subjective mild spontaneously resolving airway symptoms) do not generally have to be evaluated. Most can tolerate a second dose [82, 88, 89]. In these patients, the vaccine should be administered in a controlled environment, and patient should be kept under observation for 30 min.

Patients with moderate or severe reactions should be assessed by an allergist. In the case of the mRNA-COVID-19 vaccines, a second dose is not recommended, and a non-mRNA vaccine should be considered [90, 91]. Some studies report that administering 2 different vaccines confers immunity. However, a greater frequency of adverse events has been observed (fever, myalgia, asthenia, and headache) [92, 93]. Skin tests can be performed to evaluate the administration of subsequent doses in serial vaccines. If the result is negative, new doses can be administered as a single dose or as a split dose in a center prepared to treat anaphylaxis with a 30-min observation period. If the result is positive, stepped administration of a new dose under observation can be evaluated after agreeing with the patient [91, 94]. If the vaccine is essential, such as tetanus, and more recently the COVID-19 vaccine, desensitization can be considered [49, 95]. An alternative is periodic evaluation of the presence of IgG as evidence of immune reactivity to a previous dose [96]. However, in persons vaccinated with fewer doses than recommended, protective antibodies may not be maintained over such a long period.

Delayed reactions

Urticaria/angioedema appearing hours or days after administration of a vaccine is unlikely allergy related [97]. If necessary, a new dose can be recommended following the usual procedure, with a 30-min observation period.

Patients with delayed local reactions can receive a second dose as in usual practice, preferably in the other arm [98]. When local reactions are
type IV, vaccine can be administered via deep intramuscular injection [24]. Facial edema has been reported with Moderna vaccine, as has the association with previous cosmetic soft tissue fillers, although data are limited. Nevertheless, vaccination should not be avoided in patients previously treated with soft tissue fillers [99]. Some authors propose a 4–8-weeks interval between injection of filler and vaccination [100].

Conclusions

Vaccines play a key role in individual and public health by reducing the expansion, morbidity, and mortality of infectious diseases. Low incidence of adverse reactions to vaccines observed, even with COVID-19 vaccines, is another reason for not delaying or canceling subsequent doses. An allergy workup is only necessary in people with a specific allergy history or who have reacted to vaccines in the past. Analysis of vaccine components and clinical studies, including skin and in vitro tests, could help to identify the allergens involved and individuals at risk. All these approaches could help to eliminate barriers to vaccination and to plan the safe administration of vaccines.

Acknowledgements

The authors would like to thank Stallergenes-Greer laboratories for the funding and review of the English version of the manuscript.

Declarations

Conflict of interest
Carmelo Escudero declares that he has no conflict of interest. Patricia Prieto-Montaño declares that she has no conflict of interest. Mª Teresa Audicana received financial support from ROXALL group in the preparation of an online presentation entitled “Updates on PEG-induced allergic reactions.”

Human and animal rights and informed consent
This article does not contain any studies with human or subjects performed by any of the authors.
References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. McNeil MM, Weintraub ES, Duffy J, Jacobsen SJ, Klein NP, Hambidge SJ, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):686–78. https://doi.org/10.1016/j.jaci.2015.07.048.

2. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, et al. (2020) – “Coronavirus pandemic (COVID-19)”. Published online at OurWorldInData.org. Retrieved from: 'https://ourworldindata.org/coronavirus' [Online Resource].

3. Maltezou HC, Anastassopoulou C, Hatziantoniou S, Poland GA, Tsakris A. Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines. Vaccine. 2022;40(2):183–6. https://doi.org/10.1016/j.vaccine.2021.07.066.

4. Salman O, Topf K, Chandler R, Conklin L. Progress in immunization safety monitoring worldwide, 2010–2019. MMWR Morb Mortal Wkly Rep. 2021;70(15):547–51. https://doi.org/10.15585/mmwr.mm7015a2.

5. de Silva D, Singh C, Muraro A, Worm M, Alviani C, Cardona V, et al. Diagnosing, managing and preventing anaphylaxis: systematic review. Allergy. 2021;76(5):1493–506. https://doi.org/10.1111/all.14580.

6. Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the vaccine adverse event reporting system, 1990–2016. J Allergy Clin Immunol. 2019;143(4):1465. https://doi.org/10.1016/j.jaci.2018.12.1003.

7. Centers for Disease Control and Prevention (CDC). 2008. Syncope after vaccination–United States, January 2005–July 2007. MMWR Morb Mortal Wkly Rep. 2008 May 2;57(17):457–60.

8. Gold MS, MacDonald NE, McMurtry CM, Balakrishnan MR, Heininger U, Menning L, et al. Immunization stress-related response - redefining immunization anxiety-related reaction as an adverse event following immunization. Vaccine. 2020;38(14):3015. https://doi.org/10.1016/j.vaccine.2020.02.046.

9. Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html (Accessed on Feb 15, 2022).

10. Jackson LA, Peterson D, Nelson JC, Marcy SM, Naleway AL, Nordin JD, et al. Vaccination site and risk of local reactions in children 1 through 6 years of age. Pediatrics. 2013;131:283–9. https://doi.org/10.1542/peds.2012-2617.

11. Chiong FJ, Loewenthal M, Boyle M, Attia J. Serum sickness like reaction after influenza vaccination. BMJ Case Rep. 2015;2015:bcr2015211917. https://doi.org/10.1136/bcr-2015-211917.

12. Arkachaisri T. Serum sickness and hepatitis B vaccine including review of the literature. J Med Assoc Thai. 2002;85(Suppl 2):S607–12.

13. Nilsson L, Brockow K, Alm J, Cardona V, Caubet JC, Gomes E, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28(7):628–40. https://doi.org/10.1111/pai.12762.

14. Nagao M, Fujisawa T, Ihara T, Kino Y. Highly increased levels of IgE antibodies vaccine components in children with influenza vaccine associated anaphylaxis. J Allergy Clin Immunol. 2016;137:861–7. https://doi.org/10.1016/j.jaci.2015.08.001.

15. Arroabarren E, Anda M, Sanz ML. Anaphylaxis to pneumococcal vaccine; CRM(197): novel cause of vaccine allergy. Pediatr Allergy Immunol. 2016;27(4):433–7. https://doi.org/10.1111/pai.12548.

16. Sampath V, Rabinowitz G, Shah M, Jain S, Diament Z, Jesenak M, et al. Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives. Allergy. 2021;76(6):1640–1660. https://doi.org/10.1111/all.14840.

17. Chung EH. Vaccine allergies. Clin Exp Vaccine Res. 2014;3(1):50–7. https://doi.org/10.7774/cevr.2014.3.1.50.

18. Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37(24):3167–3178. doi: https://doi.org/10.1016/j.vaccine.2019.04.055. Squalene, a new adjuvant, is used in COVID-19 vaccines and has generated a negative impact on society, especially to conservationist groups, since it is obtained from shark liver oil.

19. Kelso JM, Greenhowt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25–43. https://doi.org/10.1016/j.jaci.2012.04.003.

20. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol. 1996;98(6 Pt 1):1058–61. https://doi.org/10.1006/jaip.2001.0749(96)80191-6.

21. Swiontek K, Morisset M, Codreanu-Morel F, et al. Drugs of porcine origin-A risk for patients with alpha-gal syndrome? J Allergy Clin Immunol Pract. 2019;7(5):1687–90. https://doi.org/10.1016/j.jaip.2018.12.005.
22. Stone CA Jr, Commins SP, Choudhary S, et al. Anaphylaxis after vaccination in a pediatric patient: further implicating alpha-gal allergy. J Allergy Clin Immunol Pract. 2019;7(1):322–24. https://doi.org/10.1016/j.jaip.2018.06.005. Alpha-gal can condition not only the administration of vaccines that may contain it, but also the intake of some food.

23. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines. Biologicals. 2003;31(4):245–9. https://doi.org/10.1016/S0377-533X(03)00063-0.

24. Audicana MT, Muñoz D, del Pozo MD, Fernández E, Castaño G, Fernández de Corres L. Allergic contact dermatitis from mercury antiseptics and derivatives: study protocol of tolerance to intramuscular injections of thimerosal. Am J Contact Dermat. 2002 Mar;13(1):3–9. https://doi.org/10.1053/ajcd.2002.29945.

25. Huang DB, Wu JJ, Tyring SK. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect. 2004;49(3):179–209. https://doi.org/10.1016/j.jinf.2004.05.018.

26. Swanson MC, Rosanoff E, Gurwith M, Deitch M, Schnurberger P, Reed CE. IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. J Infect Dis. 1987;155(5):909–13. https://doi.org/10.1093/infdis/155.5.909.

27. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Fu Gao G, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. https://doi.org/10.1016/S1473-3099(20)30831-8.

28. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92. https://doi.org/10.1016/S1473-3099(20)30843-4. Common potential allergenic excipients in COVID-19 vaccines are PEG, trometamol, and P80 but other allergenic sources must be taken account in these vaccines.

29. Kuritzky LA, Pratt M. Systemic allergic contact dermatitis after formaldehyde-containing influenza vaccination. J Cutaneous Med Surg. 2015;19(5):504–6. https://doi.org/10.1177/1077235715582306.

30. Elliman D, Dhanraj B. Safe MMR vaccination despite neomycin allergy. Lancet. 1991;337(8737):365. https://doi.org/10.1016/0140-6736(91)90995-2.

31. Kwitken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy. Am J Dis Child. 1993;147(2):128–9. https://doi.org/10.1001/archpedi.1993.02160260180005.

32. Russell M, Pool V, Kelso JM, Tomazic-Jezic VI. Vaccination of persons allergic to latex: a review of safety data in the vaccine adverse event reporting system (VAERS). Vaccine. 2004;23(5):664–7. https://doi.org/10.1016/j.vaccine.2004.06.042.

33. Hamilton RG, Brown RH, Veltri MA, Feroli ER, Primeau MN, Schauble JE, et al. Administering pharmaceuticals to latex-allergic patients from vials containing natural rubber latex closures. Am J Health Syst Pharm. 2005;62(17):1822–7. https://doi.org/10.2146/ajhp050021.

34. O’Brien TC, Maloney CJ, Tauraso NM. Quantitation of residual host protein in chicken embryo-derived vaccines by radial immunodiffusion. Appl Microbiol. 1971;21(4):780–2. https://doi.org/10.1128/am.21.4.780-782.1971.

35. Upton JEM, Hummel DB, Kasprzak A, Atkinson AR. No systemic reactions to influenza vaccination in egg-sensitized tertiary care pediatric patients. Allergy, Asthma Clin Immunol. 2012;8(1):2. https://doi.org/10.1186/1710-1492-8-2.

36. Kang J-H. Effectiveness and safety of seasonal influenza vaccination in children with underlying respiratory diseases and allergy. Korean J Pediatr. 2014;57(4):164–70. https://doi.org/10.3345/kjp.2014.57.4.164.

37. Sharma K, Perrett KP, Wood N. Yellow fever vaccination in EGG-allergic children. Pediatr Infect Dis J. 2020;39(6):e76–8. https://doi.org/10.1097/INF.0000000000002625.

38. Bédard MA, Graham F, Paradis I, Samaan K, Bégin P, Des Roches A. Single-dose yellow fever vaccination is well tolerated in egg-allergic children despite positive intradermal test to the vaccine. J Allergy Clin Immunol Pract. 2021;9(1):4170–72. https://doi.org/10.1016/j.jaip.2021.06.050. Safety of the administration of influenza and yellow fever vaccine in patients with egg allergy despite positive intradermal test.

39. Centers for Disease Control and Prevention (CDC). Flu vaccine and people with egg allergies. 2020; https://www.cdc.gov/flu/prevent/egg-allergies.htm. Accessed January 14, 2021.

40. Grohskopf LA, Alynak E, Ferdinands JM, Broder KR, Blanton LH, Talbot HK, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2021–22 Influenza Season. MMWR Recomm Rep. 2021;70(5):1–28. https://doi.org/10.15585/mmwr.r7005a1.

41. Slater JE, Rabin RL, Martin D. Comments on cow’s milk allergy and diphtheria, tetanus, and pertussis vaccines. J Allergy Clin Immunol. 2011;128(2):434; author reply 435. https://doi.org/10.1016/j.jaci.2011.06.028.

42. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. 2006;24(6):703–7. https://doi.org/10.1016/j.vaccine.2005.07.069.

43. Franceschini E, Bottau P, Caimmi S, Crisafulli G, Lucia L, Peroni D, et al. Vaccination in children with allergy to non active vaccine components. Clin Transl Med. 2015;4(3): https://doi.org/10.1186/s40169-014-0043-0.

44. Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46(7):907–22. https://doi.org/10.1111/cea.12760.
45. Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (anaphylaxis). J Allergy Clin Immunol Pract. 2021;9(2):670–5. https://doi.org/10.1016/j.jaip.2020.09.029.

46. Lukawska J, Mandaliya D, Chan AWE, Foggitt A, Bidder T, Harvey J, et al. Anaphylaxis to toremetanol excipient in gadolinium-based contrast agents for clinical imaging. J Allergy Clin Immunol Pract. 2019;7(3):1086–7. https://doi.org/10.1016/j.jaip.2018.08.035.

47. Palacios Castaño MI, Venturini Díaz M, Lobera Labairu T, González Mahave I, Del Pozo Gil MD, Blasco SA. Anaphylaxis due to excipient polysorbate 80. J Investig Allergol Clin Immunol. 2016;26(6):394–6. https://doi.org/10.18176/jiacc.0109.

48. Martín-Muñoz ME, Pereira MI, Posadas S, Sánchez-Sabaté E, Blanca M, Álvarez J. Anaphylactic reaction to diphtheria component in a child: specific IgE/IgG determinations and cross-reactivity studies. Vaccine. 2002;20(27–28):3409–12. https://doi.org/10.1016/s0264-410x(02)00228-1.

49. Ponvert C. Allergic and non-allergic hypersensitivity reactions to toxoid-containing vaccines. Arch Pediatr. 2009;16(4):391–5. https://doi.org/10.1016/j.arcped.2009.01.002.

50. Bégin P, Vu MQ, Picard M, Paradis L, Des RA. Systemic allergic reactions to gadolinium-based contrast agents for clinical imaging. J Allergy Clin Immunol. 2007. MMWR Morb Mortal Wkly Rep. 2008;57(17):457.

51. Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Harvey J, et al. Anaphylaxis to trometamol excipient in young people with egg allergy: multicentre prospective cohort study. BMJ. 2015;351: h6291. https://doi.org/10.1186/s13223-012-00613-7

52. Sakaguchi M, Inouye S. Systemic allergic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17(1):109. doi: https://doi.org/10.1186/s13223-021-00613-7.

53. Tu W, Gierada DS, Joe BN. COVID-19 Vaccination–related cutaneous reactions reported during post-marketing surveillance. Allergy Asthma Clin Immunol. 2021;17(1):109. doi: https://doi.org/10.1186/s13223-021-00613-7.

54. Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolford J, et al. Prevalence of anti-gelatine IgE antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics. 2019;16(4):391–5. https://doi.org/10.1016/j.arcped.2019.03.001.

55. Nelson MR, Oaks H, Smith LJ, Engler RM. Anaphylaxis complicating routine childhood immunization. Hemophilus influenza b conjugated vaccine. Pediatr Asthma Allergy Immunol 2000;14(4):315–21. https://doi.org/10.1089/088318707007004011.

56. Lear J, English J. Anaphylaxis after hepatitis B vaccination. Lancet. 1995;345(8959):1249. https://doi.org/10.1016/s0140-6736(95)92039-0.

57. Parisi CAS, Smaldini PL, Gervasoni ME, Maspero JF, Docena GH. Hypersensitivity reactions to the Sabin vaccine in children with cow’s milk allergy. Clin Exp Allergy. 2013;43(2):249–54. https://doi.org/10.1111/cea.12059.

58. Centers for Disease Control and Prevention (CDC). Synopsis for vaccine-related deaths—United States, January 2005–July 2007. MMWR Morb Mortal Wkly Rep. 2008;57(17):457.

59. Frakgou PC, Dimopoulou D. Serious complications of COVID-19 vaccines: a mini-review. Metabolism Open 2021;12:100145. https://doi.org/10.1016/j.metopen.2021.100145. The authors present a mini-review of side effects of licensed vaccines because, fortunately, more and more rare adverse reactions are being reported during post-marketing surveillance.

60. Alhumaid S, Al Mutair A, Al Alawi Z, Rabaan AA, Tirupathi R, Alomari MA, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17(1):109. doi: https://doi.org/10.1186/s13223-021-00613-7.

61. Nelson MR, Oaks H, Smith LJ, Engler RM. Anaphylaxis complicating routine childhood immunization. Hemophilus influenza b conjugated vaccine. Pediatr Asthma Allergy Immunol 2000;14(4):315–21. https://doi.org/10.1089/088318707007004011.

62. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, 1456

63. CDC COVID-19 Response Team, Food and Drug Administration. allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51. https://doi.org/10.15585/mmwr.mm7002e1

64. CDC COVID-19 Response Team, Food and Drug Administration. allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51. https://doi.org/10.15585/mmwr.mm7002e1

65. CDC COVID-19 Response Team, Food and Drug Administration. allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51. https://doi.org/10.15585/mmwr.mm7002e1

66. CDC COVID-19 Response Team, Food and Drug Administration. allergic reactions including anaphylaxis after receipt of the first dose of Moderna/Pfizer vaccines that mimicked SARS-CoV-2 infection. These data support that skin reactions to COVID-19 vaccination are generally minor and self-limiting and should not discourage vaccination.

67. CDC COVID-19 Response Team, Food and Drug Administration. allergic reactions including anaphylaxis after receipt of the first dose of Moderna/Pfizer vaccines that mimicked SARS-CoV-2 infection. These data support that skin reactions to COVID-19 vaccination are generally minor and self-limiting and should not discourage vaccination.

68. CDC COVID-19 Response Team, Food and Drug Administration. allergic reactions including anaphylaxis after receipt of the first dose of Moderna/Pfizer vaccines that mimicked SARS-CoV-2 infection. These data support that skin reactions to COVID-19 vaccination are generally minor and self-limiting and should not discourage vaccination.

69. CDC COVID-19 Response Team, Food and Drug Administration. allergic reactions including anaphylaxis after receipt of the first dose of Moderna/Pfizer vaccines that mimicked SARS-CoV-2 infection. These data support that skin reactions to COVID-19 vaccination are generally minor and self-limiting and should not discourage vaccination.

70. CDC COVID-19 Response Team, Food and Drug Administration. allergic reactions including anaphylaxis after receipt of the first dose of Moderna/Pfizer vaccines that mimicked SARS-CoV-2 infection. These data support that skin reactions to COVID-19 vaccination are generally minor and self-limiting and should not discourage vaccination.
68. •Ortega Rodríguez NR, Audicana Berasategui MT, de la Hoz Caballer B, Valero Santiago A. The century of mRNA vaccines: COVID-19 vaccines and allergy. J Investig Allergol Clin Immunol 2021;31(1):89–91. https://doi.org/10.18176/jiaci.0665. Regarding the previous anaphylaxis o allergic condition to contraindicate vaccines, they are not considered a contraindication and it is recommended to wait at the vaccination site and adequate surveillance.

69. Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management, and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021;76(6):1629–39. https://doi.org/10.1111/all.14739.

70. Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Koo G, Anvari S, Friedman DL, Zarnegar-Lumley S, Sza - Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Ogata AF, Cheng C, Desjardins M, Senussi Y, Sherman Shirato K, SARS-CoV-2 spike protein S1 subunit 20176/jiaci.0665. Regarding the previous anaphylaxis o allergic condition to contraindicate vaccines, they are not considered a contraindication and it is recommended to wait at the vaccination site and adequate surveillance.

71. •Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Blomkalns A, et al. Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open 2021;4(9):e2125524. https://doi.org/10.1001/jamanetworkopen.2021.25524. This case series included 22 patients with suspected adverse reactions to COVID-19 mRNA vaccines who received at least one dose. Immunological testing suggests non-IgE-mediated immune responses to PEG.

72. Koo G, Anvari S, Friedman DL, Zarnegar-Lumley S, Szaf - fron V, Kahwash BM, et al. mRNA COVID-19 vaccine safety in patients with previous immediate hypersen -itivity to pegaspargase. J Allergy Clin Immunol Pract. 2021;9(10):3546–67. https://doi.org/10.1016/j.jaip.2021.06.006.

73. •Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Blomkalns A, et al. Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open 2021;4(9):e2125524. https://doi.org/10.1001/jamanetworkopen.2021.25524. This case series included 22 patients with suspected adverse reactions to COVID-19 mRNA vaccines who received at least one dose. Immunological testing suggests non-IgE-mediated immune responses to PEG.

74. Patel GB, Chhiba KD, Chen MM, GuoA, Watts M, Cullen J, et al. COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol. Allergy Asthma Proc. 2021;42(6):515–21. https://doi.org/10.2520/app.2021.42.210075.

75. Quan PL, Sabaté-Brescó M, Guo Y, Martin M, Gastaminza G. The multifaceted mas-related G protein-coupled receptor member X2 in allergic diseases and beyond. Int J Mol Sci. 2021;22(9):4421. https://doi.org/10.3390/ijms2094421.

76. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472. https://doi.org/10.1016/j.waojou.2020.100472.

77. Brown SGA, Blackman KE, Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Australas. 2004;16(2):120–4. https://doi.org/10.1111/j.1742-6723.2004.00562.x.

78. Wolfson AR, Robinson LB, Li L, McMahon AE, Cogan AS, Fu X, et al. First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing. J Allergy Clin Immunol Pract. 2021;9(9):3308-20.e3. https://doi.org/10.1016/j.jaip.2021.06.010.

79. Seitz CS, Bröcker EB, Trautmann A. Vaccination-associated anaphylaxis in adults: diagnostic testing ruling out IgE-mediated vaccine allergy. Vaccine. 2009;27(29):3885–9. https://doi.org/10.1016/j.vaccine.2009.04.020.

80. Schuler JE, King WL, Dayneka NL, Rastelli L, Marquis E, Chad Z, et al. Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease Can J Public Health. 2011;102(3):196–9. https://doi.org/10.1007/BF03404895.

81. Wood RA, Setse R, Halsey N. Clinical Immunization Safety. Assessment (CISA) Network Hypersensitivity Working Group. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol. 2007;120(2):478-81. https://doi.org/10.1016/j.jaci.2007.04.035.

82. Marcelino J, Farinha S, Silva R, Didenko I, Proença M, Tomáz E, et al. Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine. J Allergy Clin Immunol Pract. 2021;9(6):2476–7. https://doi.org/10.1016/j.jaip.2021.03.022.

83. Bianchi L, Biondi F, Hansel K, Murgia N, Tramontana M, Stingeni L. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of intradermal testing. Allergy. 2021;76(8):2605–7. https://doi.org/10.1111/all.14839.

84. Krantz MS, Kwah JH, Stone CA, Phillips EJ, Ortega G, Banerji A, et al. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in patients with immediate reactions to the first dose. JAMA Intern Med. 2021;181(11):1530–3. https://doi.org/10.1001/jamainternmed.2021.3779.
89. Chu DK, Abrams EM, Golden DBK, Wolfson AR, Stone CA, et al. Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis. JAMA Intern Med. 2022;182(4):376–85. https://doi.org/10.1001/jamainternmed.2021.8515.

90. Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2): 100517. https://doi.org/10.1016/j.waojou.2021.100517.

91. Interim Clinical Considerations for Use of COVID-19 vaccines currently authorized in the United States. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html (last updated March 30, 2022).

92. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertrán MJ, García-Pérez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121. https://doi.org/10.1016/S0140-6736(21)01420-3.

93. Normark J, Vikström L, Gwon YD, Persson IL, Edin A, Björsell T, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. N Engl J Med. 2021;385(11):1049–51. https://doi.org/10.1056/NEJMoa2110716.

94. Mustafa SS, Ramsey A, Staicu ML. Administration of a second dose of the Moderna COVID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports. Ann Intern Med. 2021;174(8):1177–8. https://doi.org/10.7326/L21-0104.

95. AlMuhizi F, Ton-Leclerc S, Fein M, Tsoukas C, Garvey LH, Lee D, et al. Successful desensitization to mRNA COVID-19 vaccine in a case series of patients with a history of anaphylaxis to the first vaccine dose. Front Allergy. 2022;3: 825164. https://doi.org/10.3389/falgy.2022.825164.

96. Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS, Edwards KM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J. 2016;9(1):32. https://doi.org/10.1186/s40413-016-0120-5.

97. Pitlick MM, Joshi AY, Gonzalez-Estrada A, Chiarella SE. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination. Allergy Asthma Proc. 2022;43(1):40–3. https://doi.org/10.2500/aap.2022.43.210101.

98. Johnston MS, Galan A, Watsky KL, Little AJ. delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine: a case series. JAMA Dermatol. 2021;157(6):716–20. https://doi.org/10.1001/jamadermatol.2021.1214.

99. ASDS 2021. https://www.asds.net/Portals/0/PDF/secure/ASDS-SARS-CoV-2-Vaccine-Guidance.pdf.

100. Rice SM, Ferree SD, Mesinkovska NA, Kourosh AS. The art of prevention: COVID-19 vaccine preparedness for the dermatologist. Int J Womens Dermatol. 2021;7(2):209–12. https://doi.org/10.1016/j.ijwd.2021.01.007.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.